Literature DB >> 15592731

EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

M Saletu1, P Anderer, G M Saletu-Zyhlarz, M Mandl, O Arnold, J Zeitlhofer, B Saletu.   

Abstract

The aim of the present study was to identify brain regions associated with vigilance in untreated and modafinil-treated narcoleptic patients by means of low-resolution brain electromagnetic tomography (LORETA). 16 drug-free narcoleptics and 16 normal controls were included in the baseline investigation. Subsequently patients participated in a double-blind, placebo-controlled crossover study receiving a three-week fixed titration of modafinil (200, 300, 400 mg) and placebo. Measurements comprised LORETA, the Multiple Sleep Latency Test (MSLT) and the Epworth Sleepiness Scale (ESS) obtained before and after three weeks' therapy. Statistical overall analysis by means of the omnibus significance test demonstrated significant inter-group differences in the resting (R-EEG), but not in the vigilance-controlled recordings (V-EEG). Subsequent univariate analysis revealed a decrease in alpha-2 and beta 1-3 power in prefrontal, temporal and parietal cortices, with the right hemisphere slightly more involved in this vigilance decrement. Modafinil 400 mg/d as compared with placebo induced changes opposite to the aforementioned baseline differences (key-lock principle) with a preponderance in the left hemisphere. This increase in vigilance resulted in an improvement in the MSLT and the ESS. LORETA provided evidence of a functional deterioration of the fronto-temporo-parietal network of the right-hemispheric vigilance system in narcolepsy and a therapeutic effect of modafinil on the left hemisphere, which is less affected by the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592731     DOI: 10.1007/s00415-004-0543-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

Review 1.  Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.

Authors:  S Overeem; E Mignot; J G van Dijk; G J Lammers
Journal:  J Clin Neurophysiol       Date:  2001-03       Impact factor: 2.177

2.  Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy.

Authors: 
Journal:  Sleep Med       Date:  2000-07-01       Impact factor: 3.492

3.  Topographic brain mapping of EEG in neuropsychopharmacology--Part I. Methodological aspects.

Authors:  P Anderer; B Saletu; K Kinsperger; H Semlitsch
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-06

4.  Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain.

Authors:  R D Pascual-Marqui; C M Michel; D Lehmann
Journal:  Int J Psychophysiol       Date:  1994-10       Impact factor: 2.997

5.  Location of sources of evoked scalp potentials: corrections for skull and scalp thicknesses.

Authors:  J P Ary; S A Klein; D H Fender
Journal:  IEEE Trans Biomed Eng       Date:  1981-06       Impact factor: 4.538

6.  Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls.

Authors:  B Saletu; N Brandstätter; M Metka; M Stamenkovic; P Anderer; H V Semlitsch; G Heytmanek; J Huber; J Grünberger; L Linzmayer; C Kurz; K Decker; G Binder; W Knogler; B Koll
Journal:  Maturitas       Date:  1996-02       Impact factor: 4.342

Review 7.  Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA).

Authors:  B Saletu; P Anderer; G M Saletu-Zyhlarz; O Arnold; R D Pascual-Marqui
Journal:  Methods Find Exp Clin Pharmacol       Date:  2002

8.  The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort.

Authors:  C Hublin; J Kaprio; M Partinen; M Koskenvuo; K Heikkila; S Koskimies; C Guilleminault
Journal:  Ann Neurol       Date:  1994-06       Impact factor: 10.422

9.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

10.  Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.

Authors:  Udo A Zifko; Monika Rupp; Sigrid Schwarz; Harald T Zipko; Eva M Maida
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

View more
  14 in total

1.  Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks.

Authors:  Karina Stavitsky; Patrick McNamara; Raymon Durso; Erica Harris; Sanford Auerbach; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

2.  Evaluation of multiple comparison correction procedures in drug assessment studies using LORETA maps.

Authors:  Joan Francesc Alonso; Sergio Romero; Miguel Ángel Mañanas; Mónica Rojas; Jordi Riba; Manel José Barbanoj
Journal:  Med Biol Eng Comput       Date:  2015-06-04       Impact factor: 2.602

Review 3.  Parkinson's disease as a disconnection syndrome.

Authors:  Alice Cronin-Golomb
Journal:  Neuropsychol Rev       Date:  2010-04-10       Impact factor: 7.444

4.  Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by means of electroencephalographic tomography (LORETA).

Authors:  B Saletu; P Anderer; G M Saletu-Zyhlarz; D Gruber; M Metka; J Huber
Journal:  Psychopharmacology (Berl)       Date:  2004-11-03       Impact factor: 4.530

5.  Modulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat.

Authors:  Alessandro Gozzi; Valeria Colavito; Paul F Seke Etet; Dino Montanari; Silvia Fiorini; Stefano Tambalo; Angelo Bifone; Gigliola Grassi Zucconi; Marina Bentivoglio
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

6.  Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice.

Authors:  Chiraag Thakrar; Kishankumar Patel; Grainne D'ancona; Brian D Kent; Alexander Nesbitt; Hugh Selsick; Joerg Steier; Ivana Rosenzweig; Adrian J Williams; Guy D Leschziner; Panagis Drakatos
Journal:  J Sleep Res       Date:  2017-10-19       Impact factor: 3.981

7.  Modafinil Increases Awake EEG Activation and Improves Performance in Obstructive Sleep Apnea during Continuous Positive Airway Pressure Withdrawal.

Authors:  David Wang; Xiao Xue Bai; Shaun C Williams; Shu Cheng Hua; Jong-Won Kim; Nathaniel S Marshall; Angela D'Rozario; Ronald R Grunstein
Journal:  Sleep       Date:  2015-08-01       Impact factor: 5.849

8.  Modafinil effects on middle-frequency oscillatory power during rule selection in schizophrenia.

Authors:  Michael J Minzenberg; Jong H Yoon; Yaoan Cheng; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2014-06-26       Impact factor: 7.853

9.  Electroencephalogram effects of armodafinil: comparison with behavioral alertness.

Authors:  Daniela J Conrado; Michael Bewernitz; Mingzhou Ding; Jean Cibula; Christoph Seubert; Sherwin K B Sy; Stephan Eisenschenk; Hartmut Derendorf
Journal:  J Clin Pharmacol       Date:  2013-08-01       Impact factor: 3.126

Review 10.  Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Timothy I Morgenthaler; Vishesh K Kapur; Terry Brown; Todd J Swick; Cathy Alessi; R Nisha Aurora; Brian Boehlecke; Andrew L Chesson; Leah Friedman; Rama Maganti; Judith Owens; Jeffrey Pancer; Rochelle Zak
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.